Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Perspective Therapeutics, Inc. (CATX : AMEX)

• Company Description    Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash. Number of Employees: 140

• Price / Volume Information    Yesterday's Closing Price: $4.11 Daily Weekly Monthly 20 Day Moving Average: 1,220,979 shares Shares Outstanding: 74.23 (millions) Market Capitalization: $305.08 (millions) Beta: 1.18 52 Week High: $16.55 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.64% 22.86% 12 Week 111.86% 78.20% Year To Date 28.84% 20.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2401 ELLIOTT AVENUE SUITE 320 - SEATTLE,WA 98121 USA ph: 206-676-0900 fax: 509-267-3670 ir@perspectivetherapeutics.com http://www.perspectivetherapeutics.com

• General Corporate Information    Officers Johan Thijs Spoor - Chief Executive Officer and Director Lori A. Woods - Chairman Juan Graham - Chief Financial Officer Jonathan Hunt - Chief Accounting Officer Heidi Henson - Director Peer Information Perspective Therapeutics, Inc. (GSAC) Perspective Therapeutics, Inc. (CASI) Perspective Therapeutics, Inc. (ALCD.) Perspective Therapeutics, Inc. (OMNN) Perspective Therapeutics, Inc. (CGPI.) Perspective Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 46489V302 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 74.23 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.18 Market Capitalization: $305.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 24.47% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.07 Price/Cash Flow: - Price / Sales: 207.39 EPS Growth vs. Year Ago Period: -25.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 5.23% vs. Previous Quarter: 46.15% ROE 06/30/25 - - 03/31/25 - -27.91 12/31/24 - -27.05 ROA 06/30/25 - - 03/31/25 - -24.00 12/31/24 - -23.05 Current Ratio 06/30/25 - - 03/31/25 - 17.02 12/31/24 - 12.68 Quick Ratio 06/30/25 - - 03/31/25 - 17.02 12/31/24 - 12.68 Operating Margin 06/30/25 - - 03/31/25 - -5,903.47 12/31/24 - -5,535.49 Net Margin 06/30/25 - - 03/31/25 - -5,790.08 12/31/24 - -5,452.48 Pre-Tax Margin 06/30/25 - - 03/31/25 - -5,899.32 12/31/24 - -5,531.43 Book Value 06/30/25 - - 03/31/25 - 3.84 12/31/24 - 4.30 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.56 12/31/24 - 0.56

Powered by Zacks Investment Research ©